Skip to content
PeptideAI
Human trialsfertilitylibidohormone supportmood

Kisspeptin-10

The hypothalamic switch that sits upstream of GnRH, used to kick the whole reproductive axis into gear and, in imaging studies, to increase sexual and emotional brain responses.

Also known as KP-10, Metastin 45-54, Kisspeptin-112-121, Kisspeptin decapeptide, KP-10

Human trials — Studied in people, typically early phase or small — promising rather than proven.

Kisspeptin-10 has a genuinely substantial academic human literature - dose-ranging LH studies, infusion studies, and functional MRI work on sexual and emotional processing, mostly from Imperial College London. What does not exist is any trial of self-administered subcutaneous kisspeptin for libido or hormone restoration, which is how essentially everyone outside a research unit uses it.

How it works

Kisspeptin-10 is the shortest fully active C-terminal fragment of the KISS1 gene product and binds KISS1R, a Gq-coupled receptor densely expressed on GnRH neurons in the arcuate and preoptic hypothalamus. Because it acts one step above GnRH, it produces a physiological GnRH pulse rather than swamping the pituitary, which is why it stimulates rather than desensitises the axis at sensible doses. Human bolus studies show a dose-dependent LH rise peaking around 1 microgram per kilogram, with a paradoxical loss of response at 3 micrograms per kilogram - so more is genuinely not better here. Separately, functional MRI work from Imperial College has shown kisspeptin administration enhances limbic and paralimbic responses to sexual and bonding-related stimuli, which is the basis for the interest in it for low desire.

Targets: KISS1R (GPR54), GnRH neurons, LH, FSH

Dosing

ProtocolDoseFrequencyRoute
Research bolus dosing (clinical study range)Blood sampling for LH typically at 30 to 45 minutes.70 mcg – 100 mcgsingle dose per sessionintravenous
Community subcutaneous protocolOften dosed 1 to 2 hours before intended activity when used for libido.50 mcg – 200 mcgonce daily or every other daysubcutaneous
  • · Corresponds to the 1 microgram per kilogram bolus that produced maximal LH response in men. The 3 microgram per kilogram dose did not work better and in fact lost significance, so going higher is counterproductive.
  • · There is no clinical trial validating subcutaneous self-dosing of kisspeptin-10. This range reflects what people actually use, scaled from the intravenous work, and the short half-life means much of a subcutaneous dose is gone before it does anything systemically.

Titration

The dose-response curve is bell-shaped rather than linear. If a dose stops working, the correct move is usually to go down or to space doses further apart, not up.

Cycling

Continuous high-dose exposure desensitises the axis just as continuous GnRH does, so intermittent use is the sensible pattern. Most protocols run 2 to 4 weeks on with a break, though nothing about this is clinically established.

Work out your exact syringe units →

Pharmacology

Half-life
Very short - roughly 4 minutes in circulation, which is why clinical work uses infusions rather than single shots.
Onset
LH begins rising within 15 minutes of an intravenous bolus and peaks around 30 to 45 minutes.
Routes
subcutaneous, intravenous
Molecule
Endogenous decapeptide fragment (KISS1 gene product, C-terminal amide)
Sequence length
10 amino acids
Molecular weight
1302.5 Da

Handling

Diluent
Bacteriostatic water
Typical mix
2 or 3 mL
Vial sizes
5, 10 mg
Lyophilised
Freezer for long-term storage; fridge is acceptable for weeks.
Reconstituted
Refrigerated, use within about 2 to 3 weeks - shorter than most peptides.
Light sensitive
Yes — keep it out of the light

Mixing

A 5 mg vial in 2 mL gives 2.5 mg/mL, where 1 unit on a U-100 syringe is 25 mcg. Kisspeptin is one of the less stable peptides in solution.

Side effects

  • very commonNo significant adverse effects in controlled human studies— Kisspeptin has had a remarkably clean safety profile across dozens of academic human studies.
  • uncommonFlushing or warmth— Reported anecdotally with subcutaneous use.
  • uncommonHeadache
  • uncommonAxis desensitisation with continuous high dosing— Sustained exposure downregulates KISS1R and the LH response fades.

Do not use if

  • Hormone-sensitive cancers such as prostate or breast cancer - raising LH and gonadal steroids is the wrong direction.
  • Pregnancy - kisspeptin is placentally abundant and its exogenous effects in pregnancy are unstudied.
  • Active fertility treatment under a clinician's protocol, where unmonitored gonadotropin stimulation can wreck cycle timing.

Combining it

  • redundantgonadorelin — Both drive the same downstream LH pulse, just at different levels of the axis.
  • cautionhcg — hCG acts directly at the testis while kisspeptin works through the pituitary; combining them makes it impossible to tell what is doing what.
  • conflictTestosterone replacement therapy — Exogenous androgen suppresses the hypothalamus that kisspeptin is trying to stimulate, blunting the response.
  • synergypt-141 — Different mechanisms for desire - melanocortin versus reproductive axis - and sometimes combined, though no data supports the pairing.

What to monitor

  • · Baseline and follow-up LH, FSH and total testosterone if you are using it for hormone-axis purposes.
  • · Oestradiol in women, since a downstream gonadal response is the point.

Legal status

Not approved as a medicine anywhere. Sold as a research chemical.

References

  • George et al. 2011, kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men, JCEM (trial)
  • Jayasena et al. 2015, direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men, Human Reproduction 30(8):1934-41 (trial)
  • Comninos et al. 2017, kisspeptin modulates sexual and emotional brain processing in humans, Journal of Clinical Investigation (trial)

Mechanism in depth

KISS1R is Gq/11-coupled, not Gs, and that distinction is the whole story. Agonism activates phospholipase C beta, which cleaves PIP2 into IP3 and diacylglycerol, releasing intracellular calcium and activating protein kinase C. In GnRH neurons of the arcuate nucleus and preoptic area this produces sustained membrane depolarisation through TRPC4 channel opening and inhibition of inwardly rectifying potassium channels, which is a far more physiological stimulus than simply flooding the pituitary with GnRH. The result is a GnRH pulse of roughly normal amplitude and shape, and the pituitary responds to it normally. That is why kisspeptin stimulates the axis where continuous GnRH agonist exposure suppresses it: you are working one step upstream and letting the endogenous pulse generator do the shaping. Two features of this pharmacology matter in practice. First, the dose-response curve is genuinely bell-shaped in humans - the LH response peaks around 1 microgram per kilogram and is lost at 3 micrograms per kilogram - which means a non-response is at least as likely to mean too much as too little. Second, KISS1R desensitises and internalises under continuous exposure like any GPCR, so the same continuous-versus-pulsatile rule that governs GnRH analogues governs this one. Separately, kisspeptin receptors are expressed in limbic and paralimbic structures - amygdala, hippocampus, anterior cingulate - and human functional MRI work shows kisspeptin administration enhances responses to sexual and bonding stimuli and modulates resting-state connectivity. That effect is not downstream of testosterone, because it appears too fast and has been shown in designs that control for the hormonal change. It is the most interesting finding in this class and it is also the least translated into any usable protocol.

What usually goes wrong

The commonest failure is quiet and expensive: you inject subcutaneously, the peptide has a four-minute half-life, very little of it ever produces a coherent GnRH pulse, and you conclude kisspeptin does not work. Every impressive human result in this compound comes from intravenous infusion or bolus, which is not what anyone at home is doing. The second failure is dose escalation into the falling limb of the bell curve, where a bigger dose produces less LH, not more. The third is running it continuously for weeks, which desensitises KISS1R exactly the way continuous GnRH desensitises the GnRH receptor, and then reading the fading response as tolerance requiring more drug. The fourth is using it as a substitute for a diagnosis - a man with a prolactinoma or primary testicular failure will get nothing from a hypothalamic stimulus, and the months spent finding that out are months not spent treating the actual problem. Finally, kisspeptin is one of the less stable peptides in solution and degrades faster than most in a fridge, so a vial that has been sitting reconstituted for a month may genuinely be inert.

Bloodwork worth running

MarkerWhenWhy it matters
LH30 to 45 minutes after a dose for the acute response. Compare against a baseline drawn immediately before.The direct, immediate readout of whether the dose did anything at all. If LH does not move, nothing downstream will, and you are injecting an expensive saline.Act if: A flat LH at 45 minutes on a dose that should work means either the product is degraded, the route is not delivering, or you are above the top of the bell curve. Going up in dose is the wrong response to all three.
Total and free testosteroneBaseline on a morning sample, then after two to four weeks of use.The downstream endpoint anyone using this for hormone support actually cares about. Kisspeptin only helps if the whole axis below it is intact.Act if: No movement after four weeks means the limiting step is not hypothalamic and you should be looking at the testes or the pituitary instead.
FSHAlongside LH at baseline and follow-up.Rises with LH and tells you whether the pituitary response is balanced or whether you are driving one gonadotropin selectively.
OestradiolWith the four-week follow-up panel. Ask for the sensitive LC-MS/MS assay in men, not the immunoassay.In women it is the intended downstream signal. In men it rises with testosterone and is the marker that turns a good response into a symptomatic one.Act if: Symptomatic oestrogenic effects with a rising level mean lower the kisspeptin dose rather than reach for an aromatase inhibitor.
ProlactinOnce at baseline.Worth having as a baseline in anyone using kisspeptin for low libido, because hyperprolactinaemia is a common and treatable cause that kisspeptin will not fix and may mask.Act if: Above the reference range means investigate the pituitary before continuing.

Pharmacokinetics

Crosses blood-brain barrier
partial
Metabolism
Degraded by circulating peptidases, with matrix metalloproteinases MMP-2 and MMP-9 identified as cleaving kisspeptins in vitro. The C-terminal RF-amide is essential for KISS1R activation, so cleavage anywhere near that end inactivates the peptide immediately.
Elimination
Proteolytic degradation to inactive fragments. No intact renal or biliary elimination pathway of consequence.

Receptor targets

  • KISS1R (GPR54) — Sub-nanomolar to low nanomolar for kisspeptin-10 at human KISS1R in the original deorphanisation literature; a specific value was not resolved here.

    Gq/11 coupling, phospholipase C activation, IP3 and DAG generation, intracellular calcium release and PKC activation. On GnRH neurons this produces sustained depolarisation and a physiological GnRH pulse.

  • GnRH neurons (arcuate and preoptic hypothalamus)

    The functional target. Loss-of-function mutations in KISS1R cause normosmic idiopathic hypogonadotropic hypogonadism in humans, which is the cleanest possible proof that this receptor is required for reproductive function.

  • Limbic and paralimbic KISS1R (amygdala, hippocampus, anterior cingulate)

    Modulation of sexual and emotional brain processing demonstrated by functional MRI in healthy men and in men with hypoactive sexual desire disorder. This arm appears independent of the downstream gonadotropin response.

Trials

  • Kisspeptin-10 dose-ranging intravenous bolus study in healthy men 1 · 2011

    LH response to intravenous kisspeptin-10 boluses from 0.01 to 3.0 micrograms per kilogram. Established that kisspeptin-10 raises LH and increases LH pulse frequency, and that the response peaks around 1 microgram per kilogram rather than rising monotonically with dose.

  • Direct comparison of intravenous kisspeptin-10, kisspeptin-54 and GnRH in healthy men 1 · 2015

    Head-to-head gonadotropin secretion after each of the three peptides. The comparison that establishes how kisspeptin-10 differs from kisspeptin-54 and from GnRH itself in the same subjects.

  • Kisspeptin and sexual and emotional brain processing, functional MRI study Mechanistic · 2017

    Blood-oxygen-level-dependent response to sexual and bonding stimuli under kisspeptin infusion versus placebo in healthy men. Kisspeptin enhanced limbic and paralimbic activity and modulated negative mood circuitry.

  • Kisspeptin in men with hypoactive sexual desire disorder, randomised clinical trial 2 · 2023

    Sexual brain processing on functional MRI and penile tumescence in men with hypoactive sexual desire disorder, kisspeptin versus placebo. The closest thing to a therapeutic trial of kisspeptin for low desire that exists.

What to expect, and when

After an intravenous bolus, LH starts rising within about fifteen minutes and peaks at 30 to 45 minutes, with the whole excursion over inside a couple of hours. Testosterone follows a few hours behind an LH rise. The brain-imaging effects in the Imperial College studies appear during infusion, within tens of minutes, and are not waiting on any hormonal change. Subcutaneous timing in community use is poorly characterised and the reports are inconsistent, which is itself informative. Any downstream change in testicular function or fertility is measured in weeks to months, not days.

Stacking and comparisons

The stack that makes physiological sense and that nobody has tested is kisspeptin plus hCG, and the reason to be careful is not danger but attribution - hCG acts directly on the Leydig cell while kisspeptin works three levels up, so if testosterone rises you learn nothing about whether the kisspeptin did anything. Run them separately if you want interpretable bloods. Kisspeptin alongside exogenous testosterone is close to pointless, because the androgen you are injecting suppresses the hypothalamus you are trying to stimulate, and negative feedback wins. Alongside gonadorelin it is redundant: you are pulling the same lever from two positions. The pairing with PT-141 is the popular one and it is at least mechanistically independent, melanocortin versus reproductive axis, but there is no data on the combination whatsoever. If you are on a GnRH antagonist or a depot agonist, kisspeptin does nothing at all - the pituitary below it is either blocked or desensitised.

Against gonadorelin, kisspeptin acts one level higher in the axis, which means it needs an intact GnRH neuron population as well as an intact pituitary. That makes it a weaker tool in anyone with hypothalamic damage and a more physiological one in anyone whose axis is merely quiet. Against hCG, it is far gentler and far less certain: hCG bypasses everything and hits the testis directly, and it works even when the hypothalamus and pituitary are entirely suppressed, which kisspeptin absolutely does not. Against kisspeptin-54, the 10-mer has about a four-minute half-life against roughly 28 minutes, which is precisely why the IVF trigger work uses the 54-mer. Against PT-141 for libido, the difference is that PT-141 is an approved drug with phase 3 data in women, while kisspeptin has elegant mechanistic imaging trials and no approved indication anywhere. Both are real science; only one has been shown to change what happens over months in real life.

Rough cost

$25–$90/month. 5 mg research vials commonly run 40 to 90 dollars, and at 50 to 200 mcg per dose a vial lasts a long time, so raw cost is low. The real cost is the LH bloodwork needed to know whether it is doing anything, which is more expensive than the peptide. Figures are indicative and were not verified in this session.

Genuinely uncertain

  • No human pharmacokinetic dataset exists for subcutaneous kisspeptin-10, which is the only route almost anyone outside a research unit uses. Volume of distribution, clearance and protein binding are all unmeasured.
  • Blood-brain barrier penetration is marked partial. Kisspeptin acts at the median eminence and arcuate nucleus where the barrier is naturally permeable, and the limbic imaging effects imply deeper access, but a quantified penetration figure was not found.
  • The community subcutaneous dose range of 50 to 200 mcg has no trial behind it and is scaled by analogy from intravenous work in which the pharmacokinetics are completely different.
  • Whether the bell-shaped dose response seen intravenously applies at all to subcutaneous dosing is unknown.
  • There is no established cycling protocol. The two-to-four-weeks-on pattern in circulation is a reasonable inference from receptor desensitisation biology, not a validated schedule.
  • Specific KISS1R binding affinity values were not resolved from primary sources in this session.

Papers